<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-09-04-2026-shutterstock_1349493995-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-09-04-2026-shutterstock_1349493995-430x241.jpg"/></p>
<p>此次收購包括亞太地區 14 種慢性疾病產品的 MAH 權利、商標和商業權利。來源：MiniStocker / Shutterstock.com。</p>
<p>珠峯醫藥全資子公司 EverSea Medicines（新加坡）已簽署股份購買協議，條件性收購 Hasten Biopharmaceuticals，後者是 Hasten Biopharmaceuticals（亞洲）的子公司。</p>
<p>此次收購旨在增強珠峯醫藥在關鍵區域市場的存在感和商業能力。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>免疫腫瘤學（IO）- 主題智能</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>根據協議，珠峯醫藥將分三期支付總計 2.5 億美元的對價：在交易完成時支付 1.5 億美元，2028 年和 2029 年第一季度各支付 5000 萬美元，具體取決於約定的先決條件。</p>
<p>Hasten Biopharmaceuticals（亞洲）還將在交易完成後十天內向珠峯醫藥支付 2 億人民幣（2920 萬美元）的可退還押金。</p>
<p>交易完成後，珠峯醫藥將合併 Hasten Biopharmaceuticals 的財務結果。</p>
<p>此次收購包括商標和廣泛的商業權利，以及 Hasten Biopharmaceuticals 在多個亞太地區擁有的 14 種品牌慢性疾病產品的 MAH 權利。</p>
<p>在 2025 年 12 月，Hasten Biopharmaceuticals 的正常化收入為 8223 萬美元，EBITDA 為 2727 萬美元。</p>
<p>該公司專注於慢性和急性/危重護理的處方藥，目標是代謝和心血管領域。</p>
<p>珠峯醫藥的產品線專注於心血管、腎臟和代謝疾病等慢性疾病治療領域。</p>
<p>其產品包括 Nefecon、Velsipity 和 Xerava，正在亞洲市場推進新藥申請和報銷流程。</p>
<p>該公司預計此次收購將進一步加快區域產品的商業化和海外收入的生成。</p>
<p>這還將擴展珠峯醫藥現有的商業化能力，從中國擴展到亞太地區，支持市場進入和國際增長所需基礎設施的發展。</p>
<p>在 2026 年 2 月，珠峯醫藥與 Micot 簽署了獨家許可協議，以在中國和亞太地區（不包括日本）商業化 MT1013。</p>

國泰中證生物醫藥ETF

易方達恆生港股通創新藥ETF

平安中證醫療創新ETF

<p>EverSea Medicines，作為 Everest Medicines 的子公司，已簽署股份購買協議，以 2.5 億美元收購 Hasten Biopharmaceuticals。該交易包括在亞太地區 14 種慢性疾病產品的 MAH 權利、商標和商業權利。此次收購旨在增強 Everest Medicines 的市場存在感和商業能力。Hasten Biopharmaceuticals 在 2025 年 12 月報告的正常化收入為 8223 萬美元，EBITDA 為 2727 萬美元。此次收購預計將加速產品商業化並支持國際增長</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-09-04-2026-shutterstock_1349493995-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-09-04-2026-shutterstock_1349493995-430x241.jpg"/></p>
<p>The acquisition includes MAH rights, trademarks, and commercial rights for 14 chronic disease products in Asia Pacific. Credit: MiniStocker / Shutterstock.com.</p>
<div class="lb-trans"><p>此次收購包括亞太地區 14 種慢性疾病產品的 MAH 權利、商標和商業權利。來源：MiniStocker / Shutterstock.com。</p>
</div><p>Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten Biopharmaceuticals (Asia).</p>
<div class="lb-trans"><p>珠峯醫藥全資子公司 EverSea Medicines（新加坡）已簽署股份購買協議，條件性收購 Hasten Biopharmaceuticals，後者是 Hasten Biopharmaceuticals（亞洲）的子公司。</p>
</div><p>The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets.</p>
<div class="lb-trans"><p>此次收購旨在增強珠峯醫藥在關鍵區域市場的存在感和商業能力。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>Immuno-oncology (IO) - Thematic Intelligence</h4>
<div class="lb-trans"><h4>免疫腫瘤學（IO）- 主題智能</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Under the deal, Everest Medicines will pay a total consideration of $250m in three instalments: $150m at closing, and two further $50m payments due in the first quarters of 2028 and 2029, subject to agreed conditions precedent.</p>
<div class="lb-trans"><p>根據協議，珠峯醫藥將分三期支付總計 2.5 億美元的對價：在交易完成時支付 1.5 億美元，2028 年和 2029 年第一季度各支付 5000 萬美元，具體取決於約定的先決條件。</p>
</div><p>Hasten Biopharmaceuticals (Asia) will also pay a refundable deposit of 200m yuan ($29.2m) to Everest Medicines within ten days after closing.</p>
<div class="lb-trans"><p>Hasten Biopharmaceuticals（亞洲）還將在交易完成後十天內向珠峯醫藥支付 2 億人民幣（2920 萬美元）的可退還押金。</p>
</div><p>Upon closing, Everest Medicines will consolidate the financial results of Hasten Biopharmaceuticals.</p>
<div class="lb-trans"><p>交易完成後，珠峯醫藥將合併 Hasten Biopharmaceuticals 的財務結果。</p>
</div><p>The acquisition includes trademark and broad commercial rights and marketing authorisation holder (MAH) rights for 14 branded chronic disease products that are owned by Hasten Biopharmaceuticals in various Asia Pacific jurisdictions.</p>
<div class="lb-trans"><p>此次收購包括商標和廣泛的商業權利，以及 Hasten Biopharmaceuticals 在多個亞太地區擁有的 14 種品牌慢性疾病產品的 MAH 權利。</p>
</div><p>In December 2025, Hasten Biopharmaceuticals posted normalised revenue of $82.23m and EBITDA of $27.27m.</p>
<div class="lb-trans"><p>在 2025 年 12 月，Hasten Biopharmaceuticals 的正常化收入為 8223 萬美元，EBITDA 為 2727 萬美元。</p>
</div><p>The company commercialises prescription pharmaceuticals with a focus on chronic and acute/critical care, targeting the metabolic and cardiovascular segments.</p>
<div class="lb-trans"><p>該公司專注於慢性和急性/危重護理的處方藥，目標是代謝和心血管領域。</p>
</div><p>Everest Medicines has a pipeline that is focused on chronic disease therapeutic areas such as cardiovascular, kidney, and metabolic illnesses.</p>
<div class="lb-trans"><p>珠峯醫藥的產品線專注於心血管、腎臟和代謝疾病等慢性疾病治療領域。</p>
</div><p>Its products, including Nefecon, Velsipity, and Xerava, are advancing through new drug application and reimbursement processes in Asian markets.</p>
<div class="lb-trans"><p>其產品包括 Nefecon、Velsipity 和 Xerava，正在亞洲市場推進新藥申請和報銷流程。</p>
</div><p>The company expects the acquisition to further expedite regional product commercialisation and overseas revenue generation.</p>
<div class="lb-trans"><p>該公司預計此次收購將進一步加快區域產品的商業化和海外收入的生成。</p>
</div><p>It will also expand Everest Medicines’ existing commercialisation capabilities from China to the Asia Pacific, supporting market entry and the development of infrastructure needed for international growth.</p>
<div class="lb-trans"><p>這還將擴展珠峯醫藥現有的商業化能力，從中國擴展到亞太地區，支持市場進入和國際增長所需基礎設施的發展。</p>
</div><p>In February 2026, Everest Medicines signed an exclusive licence agreement with Micot to commercialise MT1013 in China and the Asia Pacific (excluding Japan).</p>
<div class="lb-trans"><p>在 2026 年 2 月，珠峯醫藥與 Micot 簽署了獨家許可協議，以在中國和亞太地區（不包括日本）商業化 MT1013。</p>
</div>

EverSea Medicines 將收購 Hasten Biopharmaceuticals